Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 55 references it cites were found in a registry or an index; none of the 54 sources its claims cite is checked for support yet.

Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status

Open access

Abstract

Importance: Breast cancer in young women has a less favorable prognosis compared with older women. Yet, comprehensive data on recent trends and how period and cohort effects may affect these trends among young women are not well-known. Objective: To evaluate breast cancer incidence among young women in the US over a 20-year period by race and ethnicity, hormone receptor status (estrogen receptor [ER] and progesterone receptor [PR]), tumor stage, and age at diagnosis, as well as how period and cohort effects may affect these trends. Design, Setting, and Participants: This cross-sectional study used data from Surveillance, Epidemiology, and End Results 17 registries (2000-2019). Women aged 20 to 49 years with a primary invasive breast cancer were included. Data were analyzed between February and June 2023. Main Outcomes and Measures: Age-standardized incidence rates (ASIR), incidence rate ratios (IRR), and average annual percent changes (AAPC) stratified by race and ethnicity, hormone receptor status, tumor stage, and age at diagnosis. Results: Out of 217 815 eligible women (1485 American Indian or Alaska Native [0.7%], 25 210 Asian or Pacific Islander [11.6%], 27 112 non-Hispanic Black [12.4%], 37 048 Hispanic [17.0%], 126 960 non-Hispanic White [58.3%]), the majority were diagnosed with an ER+/PR+ tumor (134 024 [61.5%]) and were diagnosed with a stage I tumor (81 793 [37.6%]). Overall, invasive breast cancer incidence increased (AAPC, 0.79; 95% CI, 0.42 to 1.15), with increasing trends across almost all racial and ethnic groups. ASIR increased for ER+/PR+ (AAPC, 2.72; 95% CI, 2.34 to 3.12) and ER+/PR− tumors (AAPC, 1.43; 95% CI, 1.00 to 1.87), and decreased for ER−/PR+ (AAPC, −3.25; 95% CI, −4.41 to −2.07) and ER−/PR− tumors (AAPC, −0.55; 95% CI, −1.68 to 0.60). For women aged 20 to 29 and 30 to 39 years, ASIRs were highest among non-Hispanic Black women (age 20-29 years: IRR, 1.53; 95% CI, 1.43 to 1.65; age 30-39 years: IRR, 1.15; 95% CI, 1.12 to 1.18). For women aged 40 to 49 years, ASIR was lower for non-Hispanic Black women (IRR, 0.96; 95% CI, 0.94 to 0.97) compared with non-Hispanic White women. Incidence rates increased for stages I and IV tumors but decreased for stage II and III tumors. Age-period-cohort analysis demonstrated both cohort and period effects on breast cancer incidence ( P < .001). Conclusions and Relevance: In this population-based cross-sectional analysis, an increase in breast cancer incidence rates among young US women and age-related crossover between non-Hispanic White and Black women were observed. Prevention efforts in young women need to adopt a targeted approach to address racial disparities in incidence rates observed at different age phases.

Overview

CoChat Summary

TL;DR

In a SEER-based cross-sectional study of 217,815 US women aged 20-49 diagnosed with primary invasive breast cancer from 2000-2019, breast cancer incidence increased overall, driven mainly by ER-positive tumors, while ER-negative tumors decreased. Non-Hispanic Black women had elevated incidence at ages 20-29 and 30-39, and both period and cohort effects were significant.

Key findings

Overall age-standardized breast cancer incidence increased by 0.79% annually (95% CI, 0.42 to 1.15), with a gradual increase from 2000 to 2016 (APC, 0.24; 95% CI, 0.05 to 0.42) and a steeper increase from 2016 onward (APC, 3.76; 95% CI, 1.39 to 6.19). ER+/PR+ incidence increased (AAPC, 2.72; 95% CI, 2.34 to 3.12) and ER+/PR− increased (AAPC, 1.43; 95% CI, 1.00 to 1.87), while ER−/PR+ decreased (AAPC, −3.25; 95% CI, −4.41 to −2.07). Stage I and stage IV incidence increased, whereas stage II and stage III incidence decreased. Among women aged 20-29 and 30-39 years, non-Hispanic Black women had the highest incidence rates (IRR vs non-Hispanic White, 1.53; 95% CI, 1.43 to 1.65 and 1.15; 95% CI, 1.12 to 1.18, respectively); age-period-cohort models showed strong period (P = 4.77 × 10−9) and cohort (P = 4.83 × 10−14) effects, with the cohort effect approximately twice the period effect.

Methods

Population-based, cross-sectional analysis of the SEER 17 Registries, covering 2000-2019 and nearly 27% of the US population; included women aged 20-49 years with primary invasive breast cancer, yielding a final analytic set of 217,815 women after exclusions. Calculated age-standardized incidence rates per 100,000 using the 2000 US standard population and incidence rate ratios with 95% CIs, stratified by race and ethnicity, hormone receptor status (ER/PR), AJCC stage, and age group. Used Joinpoint regression to estimate average annual percent change and age-period-cohort models to assess period and cohort effects, with sensitivity analyses in SEER 12 and SEER 22.

Limitations

The paper states that excluding missing/unknown ER or PR status could lead to underestimated age-standardized incidence rates; ERBB2 information was available in SEER only from 2010, so more intricate molecular subtypes could not be evaluated over the full 20-year period; and SEER does not provide risk factor data. Evident from the text: the study is observational and cross-sectional, so it cannot establish causality for the trends or associations described. Also evident: some race/HR/age subgroup estimates were based on very small numbers or could not be calculated, and stage was classified using different algorithms across periods (Breast-Adjusted AJCC 6th Stage for 2000-2015, Derived SEER Combined Stage Group for 2016-2017, and Derived Extent of Disease for 2018 onward), which may affect stage-trend comparability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2023.53331

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Joinpoint Analysis of Overall Incidence of Primary Invasive Breast Cancer Among US Women Aged 20 to 49 Years, 2000-2019 APC indicates annual percent changes.
Figure 1. Joinpoint Analysis of Overall Incidence of Primary Invasive Breast Cancer Among US Women Aged 20 to 49 Years, 2000-2019 APC indicates annual percent changes.CC BY · PubMed Central
Figure 2. Cohort and Period Effects on Overall Incidence of Primary Invasive Breast Cancer Among US Women Aged 20 to 49 Years Shaded areas indicate 95% CIs. In panel B, midyear point denotes the 5-year period: 2002 year denotes period 2000 to 2004; 2007 year denotes period 2005 to 2009; 2012 year denotes period 2010 to 2014; and 2017 year denotes period 2015 to 2019.
Figure 2. Cohort and Period Effects on Overall Incidence of Primary Invasive Breast Cancer Among US Women Aged 20 to 49 Years Shaded areas indicate 95% CIs. In panel B, midyear point denotes the 5-year period: 2002 year denotes period 2000 to 2004; 2007 year denotes period 2005 to 2009; 2012 year denotes period 2010 to 2014; and 2017 year denotes period 2015 to 2019.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 31 Not checked · 49 Own results and interpretations

30 more claims

Create a free account to see all 80 claims and to verify the 54 references still open.

See all claims — free account
  • It may state two separate claims as one. 31
  • The quote only partly states this claim. 2
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 55 references

Research works printed but not linked: 1

  1. Mathews? TJ, Hamilton? BE. Mean Age of Mothers is on the Rise: United States, 2000-2014. National Vital Statistics System data brief No. 232. 2000. Accessed August 11, 2023. https://pubmed.ncbi.nlm.nih.gov/26828319/

Cited by

See all 178

Metadata

Authors
Xu, S., Murtagh, S., Han, Y., Wan, F., & Toriola, A. T.
Affiliations
  • Washington University in St. Louis (US)
  • University College Dublin (IE)
Corresponding author
Toriola, Adetunji T.
Venue
JAMA Network Open
Published
2024-01-26
Volume
7
Issue
1
Pages
e2353331
ISSN
2574-3805 (ISSN-L)
OpenAlex
W4391263494
Cited by
178
References
55
Citations by year
2026: 72 · 2025: 74 · 2024: 32
FWCI
26.07
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • JAMA Network Open (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
Funders
  • National Institutes of Health
  • National Cancer Institute (R01CA246592, R37CA235602, P30CA091842)
Topics
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
breast cancer incidence, young women, racial and ethnic disparities, hormone receptor status, estrogen receptor, progesterone receptor, tumor stage, age at diagnosis, period and cohort effects, incidence trends, SEER database, American Indian and Alaska Native women, non-Hispanic Black women, Hispanic women, Asian/Pacific Islander women, non-Hispanic white women
MeSH terms
Adult, Breast Neoplasms, Cross-Sectional Studies, Ethnicity, Female, Hormones, Humans, Middle Aged, Incidence, Racial Groups, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status. https://app.cochat.ai/papers/10.1001/jamanetworkopen.2023.53331
The paper
Xu, S., Murtagh, S., Han, Y., Wan, F., & Toriola, A. T. (2024). Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.53331

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.